<u>BUZZ CHRONICLES</u> > <u>GOVERNMENT</u> <u>Saved by @SteveeRogerr</u> See On Twitter

Twitter Thread by CNN Philippines





THREAD: Senator Ping Lacson delivers a privilege speech on the government's vaccination plan | LIVE <u>https://t.co/R4i9422ym2</u>

Tweets by our digital producer @daninakpil



Lacson on Sinovac vaccine: Our officials were both tongue-tied and stuttering. I could not understand why we are being kept in the dark with the price negotiations with Sinovac while our neighboring countries cannot be more transparent about it

Lacson says countries like Thailand and Indonesia have been transparent with their vaccine procurement of Sinovac

Thailand has procured the Sinovac vaccine for ■683. 30 and ■240, respectively.

Lacson: Will somebody explain the ■1,814.75 per dose price of Sinovac vaccine?

COMPARATIVE DATA ON VACCINE PRICES

	PRICE PER DOSE			
		DVT CONTRACTS, WHO as ported by BBC ^{\1}	OFFICE OF SENATOR ANGARA (DOH DATA), as reported by News 5 ^{∖2} ₱HP	
	USD	₽HP (1USD=50Php)		
Moderna	25.0-37.0	1,250.00 — 1,850.00	1,952.00 -2,252.00	
Sinovac	13.6-29.75	680.00 — 1,487.50	1,814.75	
Pfizer/BioNTech	18.34-19.0	917.00 — 950.00	1,189.50	
AstraZeneca	4.0-8.1	200.00 — 405.00	305.00	
Novovax	16.0 (base price)	800.00	183.00	
Gamaleya			610.00	

Lacson: It appears that our initial lock in agreement will not be covered by the ludicrous 300% markdown

Lacson says he is not accusing anyone of corruption: It defies logic to suspect an attempt to overprice the vaccine.

Lacson: When there's an attempt at overpricing, isn't it logical to think na may kikita ng limpak limpak?

Lacson: Our vaccine program officials brought more confusion and bewilderment in their rush to procure Sinovac

Lacson notes that Sinovac still has no FDA approval and has no clinical phase three trial results for EUA

RELATED: Pfizer is the first developer to be granted emergency use authorization (EUA) in the Philippines, while Sinovac, AstraZeneca, and Gamaleya have submitted their EUA applications <u>https://t.co/PjMth4zeRT</u>

The Philippine government is in talks with developers to secure millions of COVID-19 vaccine doses, enough to inoculate up to 70 million people <u>https://t.co/jj8T02XpvP pic.twitter.com/ymJnLj9MNm</u>

- CNN Philippines (@cnnphilippines) January 18, 2021

Lacson presents a study of the efficacy rate of the Sinovac vaccine.

Lacson says Sinovac is one of the most expensive vaccines, yet it's efficacy rate falls behind the other brands: The issue of Sinovac is not just a matter of price but of efficacy

VACCINE EFFICACY OF SINOVAC IN BRAZIL'S CLINICAL TRIALS

SOURCE: CNN BRAZIL			CALCULATING VACCINE EFFICACY Source of Formula: CDC	
	VACCINATED	PLACEBO	VACCINE EFFICACY = 1 - RISK RATIO (RR)	
PERSONS TESTED	4,653	4,599		
SERIOUS AND MODERATE CASES	0	7	$RISK RATIO (RR) = \frac{RISK IN VACCINATED ARM}{RISK IN UNVACCINATED ARM}$ $RISK RATIO (RR) = \frac{0.0183}{0.0363} = 0.5041 (or 50.41\%)$ $VACCINE EFFICACY = 1 - 0.5041$ $VACCINE EFFICACY = 0.4958 \times 100\%$	
MILD CASES	7	24		
VERY MILD CASES	78	136		
SYMPTOMATIC CASES	85	167		
RISK (No. of Symptomatic cases/ No. of Persons Tested)	0.0183	0.0363		
			VACCINE EFFICACY = 49.58%	

RELATED: A COVID-19 vaccine developed by China's Sinovac Biotech was just 50.38% effective in late-stage trials in Brazil, significantly lower than earlier results showed, according to a statement published by the government of São Paulo https://t.co/tAReMnP3PR